UMN Pharma Inc. reported consolidated earnings results for the first half ended June 30, 2014. For the quarter, the company's net sales were JPY 1,078 million compared to JPY 24 million a year ago. Operating loss was JPY 1,796 million compared to JPY 1,497 million a year ago. Ordinary loss was JPY 1,967 million compared to JPY 1,641 million a year ago. Net loss was JPY 1,677 million or JPY 198.63 per share compared to JPY 1,166 million a year ago.

The company provided earnings forecast for the year ending December 31, 2014, 2015, 2016 and 2017. For the year ending December 31, 2014, the company expects net sales of JPY 2,186 million, operating loss of JPY 3,210 million, ordinary loss of JPY 3,424 million and net loss of JPY 2,436 million or JPY 289.11 per share.

For the year ending December 31, 2015, the company expects net sales to be in the range of JPY 6,660 million to JPY 7,663 million, operating income to be in the range of JPY 337 million to JPY 1,438 million, ordinary income to be in the range of JPY 161 million to JPY 1,263 million and net income to be in the range of JPY 118 million to JPY 950 million.

For the year ending December 31, 2016, the company expects net sales to be in the range of JPY 7,649 million to JPY 8,850 million, operating income to be in the range of JPY 358 million to JPY 1,672 million, ordinary income to be in the range of JPY 214 million to JPY 1,529 million and net income to be in the range of JPY 153 million to JPY 1,145 million.

For the year ending December 31, 2017, the company expects net sales to be in the range of JPY 10,834 million to JPY 11,735 million, operating income to be in the range of JPY 1,961 million to JPY 3,499 million, ordinary income to be in the range of JPY 1,846 million to JPY 3,384 million and net income to be in the range of JPY 1,461 million to JPY 2,611 million.